Clinical trial · Interventional
Al18F-NOTA-LM3 PET/CT in Patients With TIO
Application of Al18F-NOTA-LM3 PET/CT in the Diagnosis and Evaluation of Tumor-Induced Osteomalacia
NCT07366099CI-TRIAL-00101619recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumor-Induced Osteomalacia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic Test: 68Ga-DOTATATE | Drug | — | UNRESOLVED |
| Diagnostic Test: Al18F-NOTA-LM3 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Al18F-NOTA-LM3 and 68Ga-DOTATATE PET/CT scan
- description
- Patients of TIO PET/CT imaging: Patients will perform an Al18F-NOTA-LM3 PET/CT as well as a 68Ga-DOTATATE PET/CT.
- interventionNames
- Drug: Diagnostic Test: Al18F-NOTA-LM3
- Drug: Diagnostic Test: 68Ga-DOTATATE
Primary outcomes (1)
- measure
- Diagnostic value
- timeFrame
- From study completion to 6 months after completion.
- description
- Sensitivity and specificity of Al18F-NOTA-LM3 PET/CT for TIO in comparison with 68Ga-DOTATATE PET/CT
Secondary outcomes (1)
- measure
- standardized uptake value (SUV) of tumor
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 to 80 years. * Suspected or confirmed TIO patients. Exclusion Criteria: * Combined with other types of tumors. * Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min). * Pregnant or breast-feeding women. * Inability to perform PET/CT scans.
References
Publications (0)
Data not yet available
No reference posted for this study.